Our September edition is available to read now. The issue features companies and insight articles focused on next-generation antibodies, platform biotech technologies and the rapidly moving area of immuno-oncology.

Global viral threats such as Ebola and Zika have accelerated vaccine developers’ forays into public health and catalyzed new partnership strategies.

With the first wave of cancer immunotherapies continuing to show their potential to revolutionize treatment paradigms, major pharmaceutical companies are leaving no stone unturned in the search for winning combination therapies that harness immuno-oncology drugs.